The present disclosure relates to a combination treatment for inflammatory diseases. Specifically, the treatment described herein involves administering to a subject suffering from an inflammatory disease a combination of an anti-TNF-alpha inhibitor and at least one small molecule anti-inflammatory agent, to treat the inflammatory disease.